MedTrace Logo

Efficacy and Safety of Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes

NCT00605111 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 193

Last updated 2017-01-11

No results posted yet for this study

Summary

This trial is conducted in Asia. The aim of this trial is to investigate the efficacy and safety of biphasic insulin aspart 30 as start insulin in subjects with type 2 diabetes failing OAD therapy.

Conditions

Interventions

DRUG

biphasic insulin aspart

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-12-31
Primary Completion
2004-10-31
Completion
2004-10-31

Countries

  • Australia
  • Hong Kong
  • Malaysia
  • Philippines
  • Singapore
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00605111 on ClinicalTrials.gov